Venkat Kanamarlapudi

Professor Venkat Kanamarlapudi

Professor of Molecular Cell Biology, Biomedical Sciences
Academic Office - 204
Second Floor
Institute of Life Science 1
Singleton Campus
Available For Postgraduate Supervision


Venkateswarlu Kanamarlapudi is a Professor of Molecular Cell Biology and Pharmacology at Swansea University Medical School.

Prof. Kanamarlapudi main research interests lie in understanding GPCR-, inositol lipids- and small GTPases-mediated cell signalling in health and disease. His group recent efforts have also been focussed on the development of targeted therapy for pancreatic cancer and the improvement of LVADs.

Prof. Kanamarlapudi obtained BSc (Biology & Chemistry) from Acharya Nagarjuna University, MSc (Biochemistry) from the University of Hyderabad, MTech (Biotechnology) from IIT-Kharagpur and PhD from the University of Sheffield (researched on antifungal drugs mode of action and fungal resistance under Prof. Steve Kelly’s supervision).

Before Joining Swansea, Prof. Kanamarlapudi worked as a research scientist at AstraZeneca (India) on anti-microbial drugs, post-doctoral researcher in the School of Biochemistry at the University of Bristol on the regulation of ARF cell signalling by inositol lipids, and BBSRC David Phillips Research Fellow and Lecturer in School of Physiology and Pharmacology at the University of Bristol on ARF and inositol lipid signalling in health and disease.

Based on his research accomplishments, Prof. Kanamarlapudi has been elected as a fellow of several learned societies (FRSB, FRSC, FLSW, FABAP, FAPAS, FNABS) and received DSc (Doctor of Science) from Swansea University.

Areas Of Expertise

  • Biochemistry
  • Cell Biology
  • Pharmacology
  • Cardiovascular
  • Cancer
  • Diabetes
  • Cell Signalling
  • Molecular Medicine

Career Highlights

Teaching Interests

Membrane Trafficking

Biochemistry Literature Review and Communication

Biomolecular Research Project

Postgraduate Training


Prof. Kanamarlapudi’s group study GPCR, small GTPase and inositol lipid signalling in health and disease (cancer, type 2 diabetes, infection, cardiovascular and neurodegeneration). They are currently studying therapeutic targeting of pancreatic cancer, diabetes (GLP-1 receptor pharmacology [A]), sepsis, host-pathogen interactions, and cell signalling alterations in diabetes, cancer [B], cardiovascular and neurodegeneration. For the improvement of Left Ventricular Assisted Devices (LVADs), Prof. Kanamarlapudi’s group also studying LVAD induced shear effect on blood components and extracellular vesicles.

A. GLP-1R agonists used in type 2 diabetes (Reeds et al., 2020 F1000Res. 9 (F1000 Faculty Rev): 239

B. Cytohesin2/ARF6 regulates preadipocyte migration through the activation of ERK1/2 (Davies et al. (2014) Biochem. Pharmacol., 92: 651-660).






Award Highlights

1993       Commonwealth research scholarship

1999       BBSRC David Phillips Research Fellowship

1999       The Royal Society Dorothy Hodgkin Fellowship

2011       Fellow of the Royal Society of Biology (FRSB)

2014       Fellow of the Royal Society of Chemistry (FRSC)

2015       Fellow of Association of Biotechnology and Pharmacy (FABAP) India

2015       ABAP Senior Scientist Award, India

2017       Foreign fellow of Andhra Pradesh Academy of Sciences (FAPAS), India

2018       Fellow of National Academy of Biological Sciences (FNABS) India

2019       Fellow of Learned Society of Wales (FLSW)


Industrial: Calon Cardio

Academic: Prof. Steve Bain (SUMS), Dr Deb Roy (Chemistry, SU), Dr Murali Krishna Chilakapati (Tata Memorial Center, Mumbai, India), Dr Richard Eva and Prof. James Fawcett (Cambridge Univ.), Prof. Robert Harvey (Univ. of Sun Shine Coast, Australia), Dr William Walker (SUMS), Dr Sudhagar Pitchaimuthu (Engg., SU) and Dr Anitha Devadoss (Engg., SU)

Clinical: Prof. Bilal Al-Sarireh (SBUHB) and Prof. Saeed Ashraf (SBUHB)